ESTRING

Phase 3Small molecule

UUniversity of California, San Francisco

ESTRING is one of 9 small molecule programs targeting Vaginal Dryness. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaginal DrynessActive, not recruiting

Recurrent Urinary Tract InfectionsActive, not recruiting

Vaginal DrynessPhase 2

Active, not recruiting

Recurrent Urinary Tract InfectionsPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Recurrent Urinary Tract Infections

#DrugCompanyPhaseTrials

Monurol

MMeitheal

Approved

1 2

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—3

Avycaz

PPhiladelphia Eye Associates

Approved

—4

Merrem

BB. Braun Medical Inc.

Vagifem

1 6

ESTRING

UUniversity of California, San Francisco

Phase 3

1 7

Cipro

Bayer

Preclinical

—8

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Amikin

IInsmed Incorporated

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalActive, not recruiting

Recurrent Urinary Tract Infections

NCT06353269

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

Completed·UUniversity of California, San Francisco·Phase 2·NCT00698035·76 enrolled

Vaginal Dryness1 trial

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Active, not recruiting·PPolly A. Niravath, MD·Phase 2·NCT01984138·33 enrolled

Recurrent urinary tract infections1 trial

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Active, not recruiting·UUniversity of California, Irvine·Phase 4·NCT06353269·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ESTRING. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESTRING compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESTRING. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, San Francisco

ESTRING

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer1 trial

Vaginal Dryness1 trial

Recurrent urinary tract infections1 trial

References

Drug Info

Quick Facts

Related News